What are the side effects of the KLOW peptide blend?

No blend-level safety data

KLOW is a compounded four-peptide blend — BPC-157, TB-500, GHK-Cu, and KPV, typically a pre-blended 80 mg vial. No clinical trial has studied the combination itself; the synergy rationale rests on the components' complementary mechanisms, not on a comparative trial of the blend. Nothing below is a blend-level finding — each item is sourced from one component's own cited literature.

BPC-157 and TB-500

Neither BPC-157 nor TB-500 has completed human trials characterizing side effects. For both, the cited literature studies wound-healing mechanism largely in animal models — it neither reports nor rules out adverse effects in humans. TB-500's terminated Phase 2 human trials produced no published adverse-event data.

TB-500's side-effect evidence is covered in the thymosin beta-4 side-effects page.

and BPC-157's dosing evidence in how often BPC-157 is dosed.

GHK-Cu

GHK-Cu's strongest human evidence is topical: a small controlled trial of the topical copper-tripeptide complex after laser skin resurfacing is among the few human studies, and topical cosmetic use has a long safety record. Injectable GHK-Cu — the route relevant to KLOW — is different: it is not FDA-approved (the FDA prohibited compounded injectable preparation in 2023), and its systemic effects come from animal and limited human research, not controlled human safety trials.

KPV

KPV is an anti-inflammatory tripeptide derived from α-MSH; its cited evidence is animal-model (colitis, dermatitis) and mechanistic (NF-κB inhibition, PepT1-mediated uptake). It has not completed Phase 2 or 3 human trials, so its side-effect profile in humans is not characterized in the cited literature.

What this means for the blend

Because each component's human side-effect data is limited or absent, and no study has looked at the four together, the blend's side-effect profile cannot be stated from evidence — combining them is not shown to be safer or riskier than any component alone. Reports of mild effects (injection-site reactions, transient fatigue, mild GI changes) are anecdotal and consistent with what the individual components are reported to produce, not measured in a trial of the blend.

• No controlled trial has studied the KLOW combination; there is no blend-level side-effect data.
• BPC-157 and TB-500 have no completed human trials; the cited evidence is animal wound-healing mechanism.
• GHK-Cu's cited human evidence is topical; injectable systemic safety is not established in controlled trials.
• KPV has not completed human trials; its evidence is animal-model and mechanistic.
• Reports of mild effects are anecdotal, not measured in a trial of the blend.